Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Holding AEMD?
Track your performance easily
Earnings Data
Report Date
Feb 17, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-$0.2Last Year’s EPS
-$1.37Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 42.86%
|Next Earnings Date:Feb 17, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights Aethlon Medical's significant progress in oncology trials and successful expense reductions. However, financial challenges persist with a notable net loss, and there are delays in trial enrollments in India. Despite these concerns, the advancements in the oncology program and strategic cost management efforts are promising.Company Guidance
During the Aethlon Medical Q2 2025 earnings call, the company provided significant updates on its strategic goals and financial metrics. Aethlon's CEO, James Frakes, highlighted progress in oncology research, particularly in their Australian oncology trial, which enrolled its first two patients. The company is also working on a similar trial in India. Financially, Aethlon reported a cash balance of $6.9 million as of September 30, 2024, and a decrease in consolidated operating expenses from $3.2 million to $2.9 million year-over-year. The decrease was primarily due to a $600,000 reduction in professional fees. Despite a $500,000 increase in payroll expenses related to severance costs, the net loss for the quarter decreased to $2.8 million from $3 million in the same period of 2023. Additionally, the company anticipates a 43% rebate from the Australian government for its research expenses, further supporting its financial strategy.Advancement in Oncology Trials
The first patient was enrolled at the Royal Adelaide Hospital in Adelaide, Australia, with a second patient also enrolled. This marks a critical milestone for the oncology program, achieved within six months of having preclinical data.
Expense Reduction Success
Operating expenses decreased from $3.2 million to $2.9 million, a 9% reduction, primarily due to a $600,000 decrease in professional fees.
Progress in India Trials
Ethics committee approval received for a trial in India, with a clinical trial agreement secured. Enrollment can proceed once regulatory approval is obtained.
Cash Position
Aethlon Medical holds a cash balance of approximately $6.9 million as of September 30, 2024.
---
AEMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AEMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.41 | $0.40 | -2.44% |
| Aug 14, 2024 | $0.38 | $0.32 | -15.79% |
| Jun 27, 2024 | $0.58 | $0.50 | -13.79% |
| Feb 14, 2024 | $1.73 | $1.64 | -5.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aethlon Medical Inc (AEMD) report earnings?
Aethlon Medical Inc (AEMD) is schdueled to report earning on Feb 17, 2025, TBA Not Confirmed.
What is Aethlon Medical Inc (AEMD) earnings time?
Aethlon Medical Inc (AEMD) earnings time is at Feb 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AEMD EPS forecast?
AEMD EPS forecast for the fiscal quarter 2025 (Q3) is -$0.2.
---